These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 12820438

  • 21. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
    Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, Otake Y, Morioka Y, Takahashi C, Noda M, Wada H, Tanaka F.
    Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
    [Abstract] [Full Text] [Related]

  • 22. Maspin expression and its clinical significance in non-small cell lung cancer.
    Nakagawa M, Katakura H, Adachi M, Takenaka K, Yanagihara K, Otake Y, Wada H, Tanaka F.
    Ann Surg Oncol; 2006 Nov; 13(11):1517-23. PubMed ID: 17009165
    [Abstract] [Full Text] [Related]

  • 23. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC.
    Clin Cancer Res; 2005 Jan 01; 11(1):232-41. PubMed ID: 15671551
    [Abstract] [Full Text] [Related]

  • 24. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y, Zhang XR, Fu J, Tan W, Zhang W.
    Zhonghua Zhong Liu Za Zhi; 2004 Jun 01; 26(6):369-72. PubMed ID: 15312350
    [Abstract] [Full Text] [Related]

  • 25. Prognostic significance of polysialic acid expression in resected non-small cell lung cancer.
    Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, Li M, Yanagihara K, Inui K, Oyanagi H, Yamada T, Nakayama J, Fujimoto I, Ikenaka K, Wada H.
    Cancer Res; 2001 Feb 15; 61(4):1666-70. PubMed ID: 11245481
    [Abstract] [Full Text] [Related]

  • 26. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C, Wu YL, Gu LJ, Chen G, Weng YM, Feng WN, Zhong WZ.
    Ai Zheng; 2005 Jul 15; 24(7):846-9. PubMed ID: 16004813
    [Abstract] [Full Text] [Related]

  • 27. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.
    Lung Cancer; 2008 Oct 15; 62(1):113-9. PubMed ID: 18550205
    [Abstract] [Full Text] [Related]

  • 28. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
    Pappot H, Francis D, Brünner N, Grondahl-Hansen J, Osterlind K.
    Clin Cancer Res; 1996 Jan 15; 2(1):155-60. PubMed ID: 9816102
    [Abstract] [Full Text] [Related]

  • 29. Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer.
    Quantin X, Pujol JL, Lehmann M, Simony J, Serre I, Michel FB.
    Cancer Detect Prev; 1997 Jan 15; 21(5):418-25. PubMed ID: 9307845
    [Abstract] [Full Text] [Related]

  • 30. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M.
    Carcinogenesis; 2009 Nov 15; 30(11):1903-9. PubMed ID: 19736307
    [Abstract] [Full Text] [Related]

  • 31. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
    Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y.
    Clin Cancer Res; 2000 Feb 15; 6(2):526-30. PubMed ID: 10690534
    [Abstract] [Full Text] [Related]

  • 32. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N.
    Clin Cancer Res; 1997 Jul 15; 3(7):1195-200. PubMed ID: 9815799
    [Abstract] [Full Text] [Related]

  • 33. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
    Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR.
    J Clin Oncol; 2004 Nov 15; 22(22):4575-83. PubMed ID: 15542809
    [Abstract] [Full Text] [Related]

  • 34. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
    Muley T, Dienemann H, Ebert W.
    Anticancer Res; 2003 Nov 15; 23(5b):4085-93. PubMed ID: 14666606
    [Abstract] [Full Text] [Related]

  • 35. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
    Ishikawa S, Nakagawa T, Miyahara R, Kawano Y, Takenaka K, Yanagihara K, Otake Y, Katakura H, Wada H, Tanaka F.
    Clin Cancer Res; 2005 Feb 01; 11(3):1198-202. PubMed ID: 15709189
    [Abstract] [Full Text] [Related]

  • 36. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
    Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, Sugio K, Kohno K, Yasumoto K.
    Anticancer Res; 2005 Feb 01; 25(5):3437-43. PubMed ID: 16101161
    [Abstract] [Full Text] [Related]

  • 37. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozbudak IH, Artac M, Ozdogan M, Samur M, Kaya A, Savas B.
    Med Sci Monit; 2005 Jun 01; 11(6):HY11-20. PubMed ID: 15917726
    [Abstract] [Full Text] [Related]

  • 38. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S, Kwok Y, Krasna M, Bangalore M, Suntharalingam M.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1438-43. PubMed ID: 16029805
    [Abstract] [Full Text] [Related]

  • 39. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
    Takenaka K, Ishikawa S, Yanagihara K, Miyahara R, Hasegawa S, Otake Y, Morioka Y, Takahashi C, Noda M, Ito H, Wada H, Tanaka F.
    Ann Surg Oncol; 2005 Oct 01; 12(10):817-24. PubMed ID: 16132376
    [Abstract] [Full Text] [Related]

  • 40. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M, Steinberg SM, Mulshine JL, Linnoila RI.
    Cancer Res; 1994 May 01; 54(9):2496-503. PubMed ID: 7909277
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.